Proteflazid®: treatment of herpesvirus and mixed infections. Meta-analysis of clinical trials results.
There is a meta-analysis of clinical trials results concerning the evaluation of efficiency of the drug Proteflazid® (drops) in the treatment of adult patients with herpesvirus and mixed infections. Objective of the study: to evaluate the clinical efficacy of the drug Proteflazid® in a treatment of herpesvirus (HSV-1, HSV-2) and mixed infections in adults by meta-analysis of clinical trials. In meta-analysis, 16 scientific sources with results of controlled studies with participation of 1336 patients over 18 y.o. during 2003-2015 are included. Obtained data are indicative of efficiency of the drug Proteflazid® in the treatment of patients with herpesvirus and mixed infections. Proteflazid® induces improvement in the main clinical signs of diseases, promotes elimination of herpesviruses from organism and prevention of relapses. Proteflazid® in the therapy of various clinical forms of HHVs infection promotes the improvement in the main clinical signs of diseases, elimination of HSV-1 and HSV-2; prevention of relapses of diseases (ophthalmoherpes, genital herpes) after completion of the treatment. Therapy of mixed infections (HSV, bacteria, protozoa, fungi) using the drug Proteflazid® promotes improvement in the main clinical signs of diseases, improvement in vaginal mircoflora condition and improvement in local changes in the cervix in women with inflammatory diseases of genital organs as well as in prevention of relapses of genital inflammatory diseases and chronic pyelonephritis.